Phenex Pharmaceuticals AG is a drug discovery and development company, focused on small-molecule therapeutics.

We aim to utilize our unique team expertise and our proven drug discovery experience and platforms to develop innovative therapies for liver and gastrointestinal diseases as well as cancer.

Latest press release

Phenex AG announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I.

Recent Poster Presentations

Identification and Profiling of PX-D26116, a potent Hydroxyamidine-based IDO1 Inhibitor.PDF
CIMT 2018 Annual Meeting, May 15-17, 2018, Mainz, Germany
A novel aryl hydrocarbon receptor antagonist (PX-A24590) with anti-tumor activity in a syngeneic mouse pancreatic cancer model.PDF
CIMT 2018 Annual Meeting, May 15-17, 2018, Mainz, Germany
LXR inverse agonists inhibit de novo lipogenesis and reduce intestinal lipid and cholesterol absorption in a NAFLD mouse model.PDF
European Association for the Study of the Liver: “The International Liver Congress™ 2018”, April 11-15, 2018, Paris, France